Background
The rapid progress of the RNA sequence of a cell and a breastfeeding (SC/SNRNA-SEQ) has opened unprecedented windows in cellular diversity, but existing methods for multiplexic samples are struggling with extension and precision. Traditional techniques based on antibodies or lipid -based codes often fail to highlight evenly cells in different types or species, especially in complex clinical samples. These cell-type limitations, risk of cross-infection and loss of rare cellular populations-large-scale studies and clinical translation. To overcome these challenges, a team led by Professor Yiwei Li at the Huazhong University of Science and Technology (Hust) pioneered Toti-Neq, an innovative technology that utilizes the global presence of N-glycans on cellular and nuclear surfaces. Published as a coverage story in Research (2025, DOI: 10.34133/Research.0678), this innovation redefines how researchers approach the high performance cell profile.
Progress of the investigation
In the heart of Toti-n-seq is a mechanical protein, STV-FG, derived from the modification of the natural FBS1 anise protein. This fusion protein is unacceptable in all types of N-glycan, allowing universal labeling of cells and nuclei. By connecting the DNA bar codes to STV-FG, the group achieved accurate sample multping without cell or species restrictions. Experimental validations emphasized its well -being: flow cytometry revealed the effectiveness of the label as low as 37.5 pm. For cell membranes and 75.0 pm For nuclei, with a cross -contamination below 2% even after prolonged mixing of the sample.
In practical applications, Toti-N-Seq has proven excellent accuracy. When applied to the sequence of a nucleus, it has achieved a total accuracy of sorting (OCA) 0.987, exceeding conventional antibodies or lipids. Specifically, technology maintained rare cellular populations, such as plasmo cell dendritic cells (PDCs) in human blood samples, while reducing duplicates to 0.04% for individual cells and 0.02% for nuclei. These possibilities were further validated in 12 -level experiments, where sample discrepancies remained below 4%, proving its credibility for large -scale studies.
Future perspectives
Looking forward, the Toti-N-Seq platform is set to turn both the basic and applied research. The team plans to extend the ability to multiplex to 24-PLEX or higher, facilitating ambitious projects such as Cross-Organ Cell athletes and high performance drugs. Incorporation with epigenetic and proteinistic tools will allow multi -dimensional analyzes of a cell that will illuminate composite regulatory networks.
Clinically, Toti-N-Seq’s ability to maintain rare cellular subsets places it as a powerful tool for detecting micro-end tumors and predicting immunotherapy. Footer multiple centers will explore its diagnostic potential in groups of cancer patients. In addition to the academic community, technology compatibility with platforms such as Mobinova Microfluidics promises to rationalize industrial work flows, accelerate drug development and toxicity testing through standard, reproductive protocols.
Conclusion
Toti-n-seq represents a leap forward in a single cell genomics, facing long-term congestion in accuracy and extension of multiplexing. Utilizing the omnipresent N-Glycans, Professor Li’s team created a versatile tool that bridges the species and cell types while maintaining the biological shade. As technology moves to clinical and industrial adoption, it has the ability to democratize the high resolution cell profile by enhancing discoveries from developmental biology in personalized medicine.
Source:
Magazine report:
Lee, Y., et al. (2025). Toti-n-glycan recognition allows the universal multipurpose sequence of a single RNA core. Research. doi.org/10.34133/research.0678.
